Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Abollo-Jiménez

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Seminars in Cancer Biology|March 2, 2010
Physiological cellular reprogramming and cancerFernando Abollo-Jiménez, Rafael Jiménez, Cesar Cobaleda
Cell Cycle (Georgetown, Tex.)|March 13, 2009
Stem-cell driven cancer: "hands-off" regulation of cancer developmentCarolina Vicente-Dueñas, María Pérez-Caro, Fernando Abollo-Jiménez, et al.
Plos One|July 4, 2008
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4EPedro A Pérez-Mancera, Camino Bermejo-Rodríguez, Manuel Sánchez-Martín, et al.
Aging|December 18, 2010
The age of the target cell affects B-cell leukaemia malignancyCarolina Vicente-Dueñas, Fernando Abollo-Jiménez, Lucía Ruiz-Roca, et al.
Cell Cycle (Georgetown, Tex.)|March 29, 2014
Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisisFernando Abollo-Jiménez, Elena Campos-Sánchez, Amparo Toboso-Navasa, et al.
Cell Reports Methods|November 4, 2023
Generation of glucocorticoid-producing cells derived from human pluripotent stem cellsGerard Ruiz-Babot, Ariane Eceiza, Fernando Abollo-Jiménez, et al.
The EMBO Journal|August 21, 2012
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitorsCarolina Vicente-Dueñas, Isabel Romero-Camarero, Inés González-Herrero, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 3, 2021
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugEmilia Alors-Perez, Ricardo Blázquez-Encinas, Sonia Alcalá, et al.
Hemasphere|March 4, 2024
Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cellsTalia Velasco-Hernandez, Juan L Trincado, Meritxell Vinyoles, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Seminars in Cancer Biology|March 2, 2010
Physiological cellular reprogramming and cancerFernando Abollo-Jiménez, Rafael Jiménez, Cesar Cobaleda
Cell Cycle (Georgetown, Tex.)|March 13, 2009
Stem-cell driven cancer: "hands-off" regulation of cancer developmentCarolina Vicente-Dueñas, María Pérez-Caro, Fernando Abollo-Jiménez, et al.
Plos One|July 4, 2008
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4EPedro A Pérez-Mancera, Camino Bermejo-Rodríguez, Manuel Sánchez-Martín, et al.
Aging|December 18, 2010
The age of the target cell affects B-cell leukaemia malignancyCarolina Vicente-Dueñas, Fernando Abollo-Jiménez, Lucía Ruiz-Roca, et al.
Cell Cycle (Georgetown, Tex.)|March 29, 2014
Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisisFernando Abollo-Jiménez, Elena Campos-Sánchez, Amparo Toboso-Navasa, et al.
Cell Reports Methods|November 4, 2023
Generation of glucocorticoid-producing cells derived from human pluripotent stem cellsGerard Ruiz-Babot, Ariane Eceiza, Fernando Abollo-Jiménez, et al.
The EMBO Journal|August 21, 2012
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitorsCarolina Vicente-Dueñas, Isabel Romero-Camarero, Inés González-Herrero, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 3, 2021
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugEmilia Alors-Perez, Ricardo Blázquez-Encinas, Sonia Alcalá, et al.
Hemasphere|March 4, 2024
Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cellsTalia Velasco-Hernandez, Juan L Trincado, Meritxell Vinyoles, et al.
Pageof 1